Which company manufactures the R21/Matrix-M malaria vaccine?

ANS:A - Serum Institute of India

The R21/Matrix-M malaria vaccine is manufactured by the company known as the Oxford University spin-out, Vaccitech. This vaccine was developed in collaboration with the University of Oxford and is a promising candidate in the fight against malaria, particularly in regions where the disease is endemic. The R21/Matrix-M vaccine is notable for its use of a novel combination of antigens and an adjuvant to enhance the immune response. The Matrix-M adjuvant, developed by the pharmaceutical company Novavax, is crucial in boosting the vaccine’s efficacy. This vaccine has demonstrated significant promise in clinical trials, showing high efficacy rates in preventing malaria, which is caused by the Plasmodium falciparum parasite. The collaborative efforts in its development and the sophisticated technology behind the R21/Matrix-M vaccine represent a significant advancement in malaria vaccine research, with the potential to greatly impact global public health by providing a highly effective tool for malaria prevention and control.